Swiss startup Rivia closed a $15 million Series A to scale an agentic AI platform intended to unify and structure clinical trial data in real time and surface prioritized data‑quality issues. CEO Erik Scalfaro said the company will expand teams in Zurich and Boston and accelerate development of an 'agentic data quality' product that it projects could save sponsors $2–5 million per trial. Rivia’s technologies—Rivia detect and Rivia Spark—have been piloted in oncology trials, where they reportedly reduced manual review timelines substantially; the funding aims to move the company from case studies into broader commercial deployments with biopharma sponsors and CROs.